Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6269286 | 0.83 | NPC1 (0.60) | NPC1RAB9AEPHX2HPGDSMN1; SMN2 | |
| SCHEMBL14113144 | 0.81 | NPC1 (0.93) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL5145130 | 0.80 | NPC1 (0.69) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL92225 | 0.80 | NPC1 (0.69) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9123987 | 0.80 | NPC1 (0.69) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9732793 | 0.80 | NPC1 (0.73) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL6575574 | 0.80 | NPC1 (0.69) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL7854089 | 0.80 | NPC1 (0.56) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9389817 | 0.79 | NPC1 (0.67) | NPC1RAB9AHPGDSMN1; SMN2AR | |
| SCHEMBL9732903 | 0.79 | NPC1 (0.71) | NPC1RAB9AHPGDSMN1; SMN2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | NPC1 54/4885RAB9A 3891/4885EPHX2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.